This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s speciality care business performed particularly well, growing 18.3% thanks to the strong performance of immunology product Dupixent (dupilumab). ... For the full year, Dupixent generated sales of 3.5bn, again making gains on Sanofi’s
That included its blockbuster immunology treatment Dupixent (dupilumab), its vaccine business and a robust pipeline littered with potential candidates for rare disease, multiple sclerosis and breast and lung cancer.
So if approved, ruxolitinib cream would address a less severely-affected population than new biologic agents such as Sanofi/Regeneron’s blockbuster Dupixent (dupilumab) antibody.
The new MS data comes as Sanofi swung to a small, 10m net loss in the fourth quarter of 2019, despite another strong performance by immunology drug Dupixent (dupilumab) which grew ... Dupixent plus solid growth for Sanofi’s vaccines business lifted
If approved, Lilly’s newly acquired drug will closely compete with Sanofi/Regenerons’s Dupixent (dupilumab) which grew 142% in the last quarter to $637m.
If approved, that would be a rival to Sanofi and Regeneron’s fast-growing atopic dermatitis therapy Dupixent (dupilumab).
More from news
Approximately 22 fully matching, plus 30 partially matching documents found.
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...